Ozempic for Kidney Protection: Off-Label Evidence, Risks, and Clinical Tradeoffs
HealthRX.com
Ozempic is labeled for kidney protection in type 2 diabetes
Key numbers
- 18.7%Share of semaglutide 1 mg group with the FLOW kidney composite event, versus 23.2% on placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 1 mgKidney-indication dose on the Ozempic label, reached after at least four weeks on 0.5 mgSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 3,533 adultsAdults with type 2 diabetes and CKD randomized in the FLOW trial behind the kidney indicationSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Semaglutide
At a glance
- FDA status / An approved indication on the Ozempic injection label, not an off-label use, in adults with type 2 diabetes and CKD [1]
- Label indication / Reduce risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death [1]
- Pivotal trial / FLOW, 3,533 adults, semaglutide 1 mg weekly vs placebo, median follow-up 3.4 years, stopped early [2]
- Main result / 18.7% vs 23.2% for the composite (HR 0.76, 95% CI 0.66 to 0.88) [2]
- Dose for this indication / 1 mg weekly after at least 4 weeks on 0.5 mg [1]
- Renal dose adjustment / None recommended for renal impairment [1]
- Semaglutide tablets / Indicated for glycemic control and cardiovascular risk reduction, with no kidney indication [3]
- Label kidney warning / Acute kidney injury due to volume depletion [1]
Is Ozempic approved for kidney protection?
Yes. The Ozempic label, effective June 1, 2026, lists three indications: improving glycemic control in adults with type 2 diabetes, reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [1].
In adults with type 2 diabetes and CKD, kidney protection is therefore a labeled use, not an off-label one. The off-label question applies outside that population, most obviously CKD in people who do not have type 2 diabetes [1]. FLOW, the trial behind the indication, enrolled only adults with type 2 diabetes and CKD [2].
What people on Reddit report
Accounts from people taking semaglutide who report kidney lab changes, including improvements and drops, and differing views from nephrologists.
This medication has been a life saver for me just for kidney function.Read the source discussion
Yes I am on Ozempic & just last month my gfr dropped 10 points. Nephrologist said it could be from dehydration. Repeating tests next month.Read the source discussion
I spoke to my personal Nephrologist, and they do not believe it would be good for me.Read the source discussion
My nephrologist told me that in addition to the fact that losing weight in itself is better for your kidneys, there's some indication that these meds also have a protective effect on your kidneys. It may mean trading a few GFR points, though.Read the source discussion
The only thing that's concerning is it can cause dehydration bc you often aren't drinking enough water.Read the source discussion
What did the FLOW trial find about Ozempic and kidney disease?
FLOW randomized 3,533 adults with type 2 diabetes and CKD to semaglutide 1 mg subcutaneously once weekly or placebo, with a median follow-up of 3.4 years [2]. Participants had either an eGFR of 50 to 75 with a urine albumin-to-creatinine ratio above 300 and below 5,000, or an eGFR of 25 to under 50 with a ratio above 100 and below 5,000 [2]. The trial was stopped early at a prespecified interim analysis [2].
The primary outcome combined kidney failure (dialysis, transplant or eGFR below 15), a 50% or greater reduction in eGFR from baseline, and death from kidney or cardiovascular causes. It occurred in 18.7% of the semaglutide group and 23.2% of the placebo group, 331 versus 410 first events, hazard ratio 0.76 (95% CI 0.66 to 0.88) [2].
Other FLOW results: cardiovascular death HR 0.71; major adverse cardiovascular events 12.0% versus 14.4% (HR 0.82); all-cause death 12.8% versus 15.8% (HR 0.80); serious adverse events 49.6% versus 53.8% [2]. Benefit was not evident in the few participants taking an SGLT2 inhibitor at baseline [2].
Which semaglutide product carries the kidney indication
Ozempic injection does [1]. The kidney indication, the 1 mg dose specified for it, and the FLOW results belong to that product.
Several FDA-approved products contain semaglutide, and their labels differ. The semaglutide tablets sold as Rybelsus and Ozempic tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for those events. That label carries no kidney indication [3].
What Ozempic dose is used for kidney protection?
Ozempic starts at 0.25 mg once weekly for four weeks, a dose the label describes as a starting dose rather than a maintenance dose, then moves to 0.5 mg [1]. For the kidney indication, the label says to increase to 1 mg once weekly after at least four weeks on 0.5 mg [1]. Further increases to 2 mg are for additional glycemic control and, per the label, require at least four weeks on 1 mg; the maximum recommended dose is 2 mg weekly [1]. FLOW tested 1 mg, not 2 mg [2].
The label says a missed dose should be given within five days of the scheduled day [1]. It also says no dose adjustment is recommended for patients with renal impairment [1].
What to watch for in CKD
Gastrointestinal reactions and dehydration. In the label's pooled placebo-controlled trials in type 2 diabetes, nausea occurred in 15.8% of people on 0.5 mg and 20.3% on 1 mg versus 6.1% on placebo; vomiting in 5% and 9.2% versus 2.3%; diarrhea in 8.5% and 8.8% versus 1.9%; constipation in 5% and 3.1% versus 1.5% [1]. Any gastrointestinal reaction occurred in 32.7% and 36.4% versus 15.3%, and treatment stopped for gastrointestinal reasons in 3.1% and 3.8% versus 0.4% [1]. FLOW collected only serious adverse events and selected predefined categories, and the label states that no new serious or severe adverse reactions were identified in it [1].
Acute kidney injury. The label's kidney warning is acute kidney injury due to volume depletion. Postmarketing reports include cases requiring hemodialysis, and most occurred in people who had nausea, vomiting or diarrhea leading to dehydration. The label says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion, especially during initiation and dose escalation of Ozempic [1].
Retinopathy. In a two-year cardiovascular trial in type 2 diabetes with high cardiovascular risk, diabetic retinopathy complications occurred in 3.0% on semaglutide versus 1.8% on placebo, and in 8.2% versus 5.2% of those with retinopathy at baseline [1]. The label says patients with a history of diabetic retinopathy should be monitored, and that rapid improvement in glucose control has been associated with temporary worsening of retinopathy [1].
Pancreatitis and gallbladder disease. The label lists acute pancreatitis, with instructions to discontinue if it is suspected, and acute gallbladder disease, with gallbladder studies indicated if cholelithiasis or cholecystitis is suspected [1].
Hypoglycemia. Risk rises when Ozempic is combined with insulin or an insulin secretagogue such as a sulfonylurea, and the label says to consider a lower dose of those drugs when Ozempic is started [1].
Boxed warning. Semaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures; whether it causes them in humans is unknown. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1].
Questions worth asking
What FLOW does not settle
FLOW enrolled only adults with type 2 diabetes, so its result does not show whether semaglutide protects kidneys in CKD without diabetes [2]. Participants had to have an eGFR of at least 25 to enter, so the result does not directly address people who started below that level [2].
Compounded semaglutide
Compounded semaglutide is not FDA approved and is not reviewed for safety, effectiveness or quality before marketing [4]. The kidney indication and the FLOW results belong to the FDA-approved Ozempic product [1][2].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Is Ozempic FDA-approved for kidney protection?
What Ozempic dose was used for kidney protection?
Does Ozempic harm the kidneys?
Do the semaglutide tablets carry the kidney indication?
Can people without type 2 diabetes use Ozempic for kidney protection?
Is a dose adjustment needed for kidney disease?
References
Show all 7 referencesHide references
- U.S. National Library of Medicine, DailyMed. Ozempic injection (Novo Nordisk) prescribing information. Ozempic injection (Novo Nordisk) label
- Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121.
- U.S. National Library of Medicine, DailyMed. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) prescribing information. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) label
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA.
- Reddit participants. Ozempic and Kidney Damage (r/Ozempic). Accessed 2026-11-11.
- Reddit participants. Any one on " Ozempic" (r/kidneydisease). Accessed 2026-11-11.
- Reddit participants. ozempic (r/kidneydisease). Accessed 2026-11-11.